Prevalence of Carcinoid Syndrome (CS) in the European Union (EU)

#2035

Introduction: Epidemiologic data on CS, which typically occurs in patients with advanced midgut or lung neuroendocrine tumors (NET), are scarce and appear to be heterogeneous across countries.

Aim(s): To estimate the prevalence rate and total number of patients with CS in the EU.

Materials and methods: MEDLINE and Embase were systematically searched over the period Jan 2010–Feb 2016, without limit of language. Grey literature including web sources and conference proceedings was reviewed. Prevalence rate of CS was derived from the prevalence rate of overall NET in the EU and the proportion of NET patients with CS at each primary tumor site (midgut or lung; CS being very rare elsewhere). EU population size as of 1 Jan 2015 was used to estimate total number of CS patients. Sensitivity analyses evaluated the robustness of estimates using alternative data for the distribution of primary tumors and the proportion of CS among NETs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Nayroles G

Authors: Nayroles G, Bergamasco A, Mouchet J, Moride Y,

Keywords: neuroendocrine tumors, carcinoid syndrome, prevalence rate, orphan disease, Europe,